NCT01338090View on ClinicalTrials.gov

89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

CompletedOBSERVATIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Neuroendocrine Tumors
Interventions
DRUG

89Zr-bevacizumab

Intravenous injection 120 MBq

DRUG

Everolimus

Oral use, 10 mg per day

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University Medical Center Groningen

OTHER